Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. The 2002 fiscal year was defined by the completion of the acquisition of Immunex Corporation on July 15, 2002, for approximately $17.8 billion. This transaction significantly expanded Amgen's product portfolio, adding ENBREL (etanercept) and Kineret (anakinra), and diversified its pipeline in inflammation and oncology. The company operates in a single business segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | 2002 | 2001 |
|---|---|---|
| Total Revenues | $5,523.0 | $4,015.7 |
| Product Sales | $4,991.2 | $3,511.0 |
| Net (Loss) Income | $(1,391.9) | $1,119.7 |
| Diluted EPS | $(1.21) | $1.03 |
| Operating Cash Flow | $2,248.8 | $1,480.2 |
| Total Assets | $24,456.3 | $6,443.1 |
| Long-term Debt | $3,047.7 | $223.0 |
| Cash & Equivalents | $1,851.7 | $689.1 |
Product Sales Breakdown (2002): EPOGEN ($2,260.6M), NEUPOGEN ($1,379.6M), Neulasta ($463.5M), Aranesp ($415.6M), and ENBREL ($362.1M, post-acquisition).
Material Changes vs. Prior Period
- Net Loss vs. Profit: The company reported a net loss of $1.39 billion in 2002 compared to a net income of $1.12 billion in 2001. This reversal was primarily driven by a one-time, non-cash write-off of $2.99 billion for acquired in-process research and development (IPR&D) related to the Immunex acquisition.
- Revenue Growth: Total revenues increased 37% to $5.52 billion, driven by strong sales of Neulasta, Aranesp, and the inclusion of ENBREL sales from July 2002.
- Balance Sheet Expansion: Total assets nearly quadrupled to $24.46 billion due to the acquisition, resulting in $9.87 billion in goodwill and $4.80 billion in intangible assets.
- Debt Structure: Long-term debt increased significantly to $3.05 billion following the issuance of $3.95 billion in 30-year zero-coupon senior convertible notes in March 2002.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Growth Drivers: Future growth is expected to be driven by Neulasta, ENBREL, and Aranesp. Management anticipates continued conversion of NEUPOGEN patients to Neulasta, which will impact NEUPOGEN sales but increase combined sales.
- Capital Expenditures: Estimated spending on capital projects for 2003 is projected between $1.3 billion and $1.5 billion, focusing on manufacturing expansions in Puerto Rico, Rhode Island, and Seattle.
- Reimbursement Risks: The company highlighted risks regarding third-party payor reimbursement rates, specifically noting a new CMS rule effective January 1, 2003, that significantly reduced reimbursement for Aranesp in the hospital outpatient setting.
Key Risks & Contingencies:
- Supply Constraints: ENBREL sales were impacted by supply constraints in 2002. The company relies heavily on third-party manufacturer Boehringer Ingelheim Pharma KG (BI Pharma) and its own Rhode Island facility. Future sales depend on the successful ramp-up of these facilities and a new Genentech facility.
- Legal Proceedings: Significant litigation includes patent disputes with Genentech (regarding NEUPOGEN) and Transkaryotic Therapies/Aventis (regarding EPOGEN). Additionally, the company is involved in multiple Average Wholesale Price (AWP) class action lawsuits.
- Regulatory Approval: Future success depends on obtaining regulatory approvals for product candidates in nephrology, oncology, and inflammation.
Investor Verification Checklist
- IPR&D Write-off Impact: Verify the non-cash nature of the $2.99 billion charge and its exclusion from operating cash flow analysis.
- ENBREL Supply Chain: Confirm the status of FDA approvals for the Rhode Island facility and the Genentech manufacturing site to assess future ENBREL revenue potential.
- Reimbursement Policy Changes: Monitor the impact of the new CMS reimbursement rule for Aranesp on hospital outpatient sales and potential ripple effects on other payors.
- Convertible Notes: Review the terms of the $3.95 billion zero-coupon convertible notes, specifically the potential for cash settlement or share conversion upon repurchase dates starting in 2005.
- Legal Settlements: Track the status of the AWP litigation and the Genentech patent dispute, as outcomes could result in significant liabilities or market restrictions.